Liberty One戰術收益主動型ETF LOTI 深 滬
已收盤 08-14 16:00:00 美东时间
26.2043
-0.048
-0.18%
華盛通- 最 高26.2043
- 今 開26.21
- 成交量 19股
- 最 低 26.2043
- 昨 收 26.2522
- 總市值 4716.27万
- 52周最高 26.5095
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 24.995
- 委 比 0.03%
- 總股本 179.98万
- 歷史最高 26.5095
- 量 比 0.00
- 振 幅 0.00%
- 歷史最低 24.995
- 每 手 1
- 風險率 0.37%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多ADC Therapeutics Q2 Earnings Preview
ADC Therapeutics (ADCT) is scheduled to announce Q2 earnings results on Thursday, August 13th, before market open. The consensus EPS Estimate is -$0.22 (+12.0% Y/Y) and the consensus Revenue Estimate ...
08-13 03:06
ADC Therapeutics Halts LOTIS-10 Liver-Impairment Study: What It Means for Zynlonta and Investors
ADC Therapeutics Ltd ($ADCT) announced an update on their ongoing clinical stud...
07-21 00:30
Why Is ADC Therapeutics Stock Falling Thursday?
ADC Therapeutics stock plunges premarket as LOTIS-3 trial shows elevated serious, Grade 5 adverse events despite meeting its primary endpoint.
06-04 20:44
ADC Therapeutics Announces Topline Data From Phase 3 LOTIS-5 Confirmatory Trial Evaluating ZYNLONTA In Combination With Rituximab In Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma
Company to host conference call today at 4:30 p.m. EDTLAUSANNE, Switzerland, June 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT) today announced topline data from its Phase 3 LOTIS-5 confirmatory trial
06-04 04:13
ADC Therapeutics outlines $600M–$1B peak revenue target for ZYNLONTA as LOTIS-5 and LOTIS-7 advance
Earnings Call Insights: ADC Therapeutics SA (ADCT) Q4 2025 Management View CEO Ameet Mallik highlighted a strategic plan focused on ZYNLONTA with optimized life cycle management, including advancing L...
03-10 22:00
